Table-IV.
Comparison of adverse events post-treatment (n, %).
| Variables | TACE+lenvatinib group (n=46) | TACE group (n=57) | χ2/Fisher | P |
|---|---|---|---|---|
| Abdominal pain | 19 (41.30) | 23 (40.35) | 0.010 | 1.000 |
| Fever | 12 (26.09) | 15 (26.32) | 0.001 | 1.000 |
| Nausea and vomiting | 13 (28.26) | 15 (26.32) | 0.049 | 0.828 |
| Fatigue | 24 (52.17) | 21 (36.84) | 2.432 | 0.162 |
| Decreased albumin | 22 (47.83) | 27 (47.37) | 0.002 | 1.000 |
| Decreased PLT | 16 (34.78) | 19 (33.33) | 0.024 | 1.000 |
| Decreased WBC | 13 (28.26) | 12 (21.05) | 0.720 | 0.489 |
| Elevated AST | 15 (32.61) | 16 (28.07) | 0.249 | 0.669 |
| Hypertension | 6 (13.04) | 0 (0.0) | 7.895 | <0.05 |
| Hand-foot syndrome | 3 (6.52) | 0 (0.0) | 3.829 | 0.086 |
| Diarrhea | 5 (10.87) | 0 (0.0) | 6.512 | <0.05 |
| Gingival bleeding | 7 (15.22) | 0 (0.0) | 9.306 | <0.05 |